Czech National Bank Boosts Holdings in Boston Scientific Co. (NYSE:BSX)

Czech National Bank raised its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 6.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 319,328 shares of the medical equipment provider's stock after acquiring an additional 19,339 shares during the quarter. Czech National Bank's holdings in Boston Scientific were worth $28,522,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of BSX. Values First Advisors Inc. bought a new stake in shares of Boston Scientific during the 3rd quarter valued at about $28,000. Dunhill Financial LLC boosted its holdings in shares of Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock worth $28,000 after buying an additional 152 shares in the last quarter. Global Wealth Strategies & Associates boosted its holdings in shares of Boston Scientific by 423.7% during the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after buying an additional 250 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. bought a new stake in shares of Boston Scientific in the 3rd quarter valued at $30,000. Finally, Capital Performance Advisors LLP acquired a new position in shares of Boston Scientific during the 3rd quarter valued at $30,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

BSX traded down $0.10 during trading on Monday, hitting $94.78. 4,213,810 shares of the company traded hands, compared to its average volume of 5,358,299. Boston Scientific Co. has a one year low of $59.61 and a one year high of $97.13. The stock's fifty day moving average is $90.16 and its 200 day moving average is $84.02. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The firm has a market cap of $139.69 billion, a P/E ratio of 78.33, a price-to-earnings-growth ratio of 2.67 and a beta of 0.80.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.59 by $0.04. The firm had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The company's revenue was up 19.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.50 EPS. As a group, equities analysts predict that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Analysts Set New Price Targets

BSX has been the subject of several research analyst reports. Mizuho lifted their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the company an "outperform" rating in a research note on Thursday, October 24th. Royal Bank of Canada boosted their target price on Boston Scientific from $95.00 to $98.00 and gave the company an "outperform" rating in a research report on Thursday, October 24th. TD Cowen increased their price target on Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Thursday, December 12th. StockNews.com downgraded Boston Scientific from a "buy" rating to a "hold" rating in a report on Monday, November 4th. Finally, JPMorgan Chase & Co. increased their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an "overweight" rating in a report on Monday, December 16th. Three analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $97.26.

Insider Transactions at Boston Scientific

In related news, EVP John Bradley Sorenson sold 4,119 shares of the firm's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the transaction, the executive vice president now directly owns 35,319 shares of the company's stock, valued at approximately $3,179,416.38. This trade represents a 10.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 4,877 shares of the business's stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total transaction of $446,879.51. Following the sale, the director now directly owns 39,398 shares in the company, valued at $3,610,038.74. The trade was a 11.02 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 29,989 shares of company stock worth $2,702,261. 0.50% of the stock is owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.